Sanofi (NASDAQ:SNY) to Post Q1 2024 Earnings of $0.94 Per Share, Leerink Partnrs Forecasts

Sanofi (NASDAQ:SNY) – Equities researchers at Leerink Partnrs cut their Q1 2024 earnings estimates for Sanofi in a research note issued to investors on Tuesday, April 16th. Leerink Partnrs analyst D. Risinger now expects that the company will earn $0.94 per share for the quarter, down from their previous estimate of $0.98. The consensus estimate for Sanofi’s current full-year earnings is $4.15 per share. Leerink Partnrs also issued estimates for Sanofi’s FY2024 earnings at $3.97 EPS, FY2025 earnings at $4.44 EPS and FY2028 earnings at $5.34 EPS.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.94 by ($0.05). The company had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $13.02 billion. Sanofi had a return on equity of 27.47% and a net margin of 12.56%.

Several other research analysts have also recently weighed in on SNY. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Morgan Stanley assumed coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price target on the stock. Finally, TheStreet cut shares of Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $55.00.

Sanofi Stock Up 2.0 %

SNY stock opened at $46.30 on Thursday. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The company’s 50 day moving average is $47.52 and its 200 day moving average is $48.62. The stock has a market cap of $117.12 billion, a price-to-earnings ratio of 19.62, a price-to-earnings-growth ratio of 1.72 and a beta of 0.61. Sanofi has a 1-year low of $42.63 and a 1-year high of $57.82.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Boston Partners grew its holdings in shares of Sanofi by 1.9% in the fourth quarter. Boston Partners now owns 13,032,746 shares of the company’s stock worth $648,617,000 after purchasing an additional 245,682 shares during the last quarter. BlackRock Inc. lifted its stake in Sanofi by 2.5% in the first quarter. BlackRock Inc. now owns 10,047,856 shares of the company’s stock worth $546,804,000 after acquiring an additional 249,619 shares during the period. Morgan Stanley lifted its stake in Sanofi by 19.3% in the fourth quarter. Morgan Stanley now owns 7,733,069 shares of the company’s stock worth $374,513,000 after acquiring an additional 1,251,199 shares during the period. Invesco Ltd. lifted its stake in Sanofi by 2.3% in the first quarter. Invesco Ltd. now owns 5,077,848 shares of the company’s stock worth $260,697,000 after acquiring an additional 112,404 shares during the period. Finally, Nuveen Asset Management LLC lifted its stake in Sanofi by 7.3% in the fourth quarter. Nuveen Asset Management LLC now owns 4,503,957 shares of the company’s stock worth $223,982,000 after acquiring an additional 305,781 shares during the period. Institutional investors own 10.04% of the company’s stock.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be issued a $1.478 dividend. This is a boost from Sanofi’s previous annual dividend of $1.38. The ex-dividend date is Thursday, May 9th. This represents a dividend yield of 2.98%. Sanofi’s dividend payout ratio (DPR) is currently 58.47%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.